If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndrome
SID increases serum IgG levels in GBS patients as predicted by the current PK model, but does not improve clinical outcomes and increases the risk of serious adverse events. Model-informed precision dosing may guide individualization of treatment.
Authors
- Ruth Huizinga (ORCID: https://orcid.org/0000-0002-9563-4860)
- Birgit C. P. Koch (ORCID: https://orcid.org/0000-0002-1202-3643)
- Krista Kuitwaard (ORCID: https://orcid.org/0000-0002-1003-500X)
- Sander J van Tilburg (ORCID: https://orcid.org/0000-0003-3983-9797)
- Christa Walgaard (ORCID: https://orcid.org/0000-0003-0483-3280)
- Sebastiaan D. T. Sassen (ORCID: https://orcid.org/0000-0002-4525-638X)
- Pieter A. van Doorn
- Bart C. Jacobs
Institutions
- Erasmus MC (NL)
- Albert Schweitzer Ziekenhuis (NL)
- IJsselland Ziekenhuis (NL)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1002/acn3.52313
- Citations
- 2
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Prinses Beatrix Spierfonds